We are live on
!
Find out more
TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
Turnover
15.59%
1-Year Est. Return
18.15%
This Fund
S&P 500
This Quarter
Est. Return
+2.9%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.56B
AUM Growth
-$71.2M
(-2.7%)
Cap. Flow
-$99.6M
Cap. Flow
% of AUM
-3.9%
Top 10 Holdings %
Top 10 Hldgs %
40.31%
Holding
186
New
9
Increased
27
Reduced
32
Closed
20
Avg Time Held
4.2
years
Top 10 Avg Time Held
3.2
years
Top 20 Avg Time Held
4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$20M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$14.2M |
| 3 |
Amgen
AMGN
|
+$14.1M |
| 4 |
Insulet
PODD
|
+$13.3M |
| 5 |
Baxter International
BAX
|
+$11.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$31.7M |
| 2 |
Cigna
CI
|
+$22.5M |
| 3 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$22.3M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$13.8M |
| 5 |
Sarepta Therapeutics
SRPT
|
+$13.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.28% |
| 2 | Real Estate | 2.09% |
| 3 | Miscellaneous | 1.37% |
| 4 | Industrials | 0.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
Intellia Therapeutics
NTLA
$1.6B
| $6.29M | 0.25% |
154,269
| – | – |
2021 Q1
9 quarters
|
|
77
LTC Properties
LTC
$2.33B
| $6.02M | 0.24% |
182,293
| – | – |
2014 Q3
35 quarters
|
|
78
Sabra Healthcare REIT
SBRA
$4.9B
| $6.01M | 0.24% |
510,660
| – | – |
2014 Q3
35 quarters
|
|
79
Smith & Nephew
SNN
$11.7B
| $5.86M | 0.23% |
181,710
| – | – |
2017 Q4
22 quarters
|
|
|
KDNY
80
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $5.8M | 0.23% |
150,863
+67,363
| +81% | +$1.73M |
2023 Q1
1 quarter
|
|
81
West Pharmaceutical
WST
$26.4B
| $5.75M | 0.23% |
15,036
| – | – |
2023 Q1
1 quarter
|
|
82
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $5.61M | 0.22% |
176,483
| – | – |
2021 Q4
6 quarters
|
|
83
LivaNova
LIVN
$4.19B
| $5.58M | 0.22% |
108,480
+44,600
| +70% | +$2.09M |
2023 Q1
1 quarter
|
|
|
MDRX
84
DELISTED
Veradigm Inc. Common Stock
MDRX
| $5.4M | 0.21% |
428,580
| – | – |
2022 Q3
3 quarters
|
|
85
Agilent Technologies
A
$49.1B
| $5.19M | 0.2% |
43,191
| – | – |
2019 Q2
16 quarters
|
|
86
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $4.46M | 0.17% |
411,101
-45,679
| -10% | -$391K |
2023 Q1
1 quarter
|
|
87
uniQure
QURE
$1.45B
| $4.08M | 0.16% |
356,280
-296,166
| -45% | -$5.61M |
2015 Q3
31 quarters
|
|
88
Cencora
COR
$64.2B
| $3.93M | 0.15% |
20,417
| – | – |
2022 Q4
2 quarters
|
|
89
Medical Properties Trust
MPT
$1.83B
| $3.81M | 0.15% |
411,743
| – | – |
2014 Q3
35 quarters
|
|
90
BeOne Medicines Ltd
ONC
$39.8B
| $3.74M | 0.15% |
20,952
| – | – |
2017 Q4
22 quarters
|
|
91
Ionis Pharmaceuticals
IONS
$7.1B
| $3.6M | 0.14% |
87,840
| – | – |
2017 Q4
22 quarters
|
|
92
BioCryst Pharmaceuticals
BCRX
$2.06B
| $3.55M | 0.14% |
504,528
| – | – |
2022 Q1
5 quarters
|
|
|
RETA
93
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $3.49M | 0.14% |
34,250
+16,400
| +92% | +$1.55M |
2023 Q1
1 quarter
|
|
94
Teva Pharmaceutical Industries Limited
TEVA
$47.5B
| $3.46M | 0.14% |
459,651
| – | – |
2013 Q2
40 quarters
|
|
95
Welltower
WELL
$167B
| $3.36M | 0.13% |
41,484
| – | – |
2016 Q4
26 quarters
|
|
96
Healthcare Realty
HR
$5.84B
| $3.29M | 0.13% |
174,686
| – | – |
2016 Q4
26 quarters
|
|
97
Ventas
VTR
$43.2B
| $3.15M | 0.12% |
66,681
| – | – |
2014 Q3
35 quarters
|
|
98
iShares Biotechnology ETF
IBB
$10.4B
| $3.12M | 0.12% |
24,569
| – | – |
2022 Q3
3 quarters
|
|
99
Healthpeak Properties
DOC
$12.9B
| $3.02M | 0.12% |
150,392
| – | – |
2016 Q4
26 quarters
|
|
100
DELISTED
Akero Therapeutics
AKRO
| $2.87M | 0.11% |
+61,497
| New | +$2.82M |
2023 Q2
0 quarters
|
|
Similar funds
AWS
JP
VCM
FCFS
FCB
BWM
Tekla Capital Management's Q2 2023 Portfolio in Review
As of Q2 2023, Tekla Capital Management held 186 positions worth $2.56B, down 2.7% from $2.63B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Tekla Capital Management withdrew a net $99.6M in Q2 2023, closing 20 positions and reducing 32 holdings. Its most notable exit was Travere Therapeutics, an estimated $9.41M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Real Estate and Miscellaneous.
Against the trend, Tekla Capital Management opened a new position in Insulet worth $12.6M.
- Tekla Capital Management's largest Q2 2023 buy was Insulet: 43,847 shares worth $12.6M.
- Tekla Capital Management added most to Merck in Q2 2023, an estimated $20M increase.
- Tekla Capital Management's biggest Q2 2023 reduction was Eli Lilly, cutting an estimated $31.7M.
- Tekla Capital Management fully exited Travere Therapeutics in Q2 2023, selling an estimated $9.41M.
- Tekla Capital Management's ten largest holdings make up 40% of its $2.56B portfolio in Q2 2023.
- Tekla Capital Management opened 9 new positions and closed 20 in Q2 2023.
- Tekla Capital Management's portfolio value fell 2.7% quarter-over-quarter to $2.56B.
Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.